Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease.

Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, Tariot PN, Raket LL.

Alzheimers Dement (N Y). 2019 May 20;5:164-174. doi: 10.1016/j.trci.2019.04.001. eCollection 2019.

PMID:
31193334
2.

Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.

Tort-Merino A, Olives J, León M, Peñaloza C, Valech N, Santos-Santos MA, Càmara E, Grönholm-Nyman P, Martínez-Lage P, Fortea J, Molinuevo JL, Sánchez-Valle R, Laine M, Rodríguez-Fornells A, Rami L.

J Alzheimers Dis. 2019 Jun 6. doi: 10.3233/JAD-190046. [Epub ahead of print]

PMID:
31177219
3.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.

Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8.

4.

Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.

Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B.

J Prev Alzheimers Dis. 2019;6(3):157-163. doi: 10.14283/jpad.2019.14.

PMID:
31062825
5.

Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

6.

APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals.

Cacciaglia R, Molinuevo JL, Falcón C, Sánchez-Benavides G, Gramunt N, Brugulat-Serrat A, Esteller M, Morán S, Fauria K, Gispert JD; ALFA study.

Neuroimage Clin. 2019 Apr 8;23:101818. doi: 10.1016/j.nicl.2019.101818. [Epub ahead of print]

7.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

8.

CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.

Falcon C, Monté-Rubio GC, Grau-Rivera O, Suárez-Calvet M, Sánchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019 Apr 1;23:101801. doi: 10.1016/j.nicl.2019.101801. [Epub ahead of print]

9.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
10.

Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.

Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Pizzini F, Rossini PM, Salvatore M, Schönknecht P, Soricelli A, Del Percio C, Hensch T, Hegerl U, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium.

J Alzheimers Dis. 2019;69(1):49-58. doi: 10.3233/JAD-181016.

PMID:
30958351
11.

Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.

Skouras S, Falcon C, Tucholka A, Rami L, Sanchez-Valle R, Lladó A, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019;22:101777. doi: 10.1016/j.nicl.2019.101777. Epub 2019 Mar 12.

12.

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, Pavia J, Niñerola-Baizán A, Perissinotti A, Lomeña F, Minguillon C, Fauria K, Zetterberg H, Blennow K, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study.

Alzheimers Res Ther. 2019 Mar 21;11(1):27. doi: 10.1186/s13195-019-0478-z.

13.

Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?

Farrar G, Molinuevo JL, Zanette M.

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1299-1308. doi: 10.1007/s00259-019-04282-y. Epub 2019 Mar 13.

14.

European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol.

Solomon A, Kivipelto M, Molinuevo JL, Tom B, Ritchie CW; EPAD Consortium.

BMJ Open. 2019 Feb 19;8(12):e021017. doi: 10.1136/bmjopen-2017-021017.

15.

Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort.

Salvadó G, Brugulat-Serrat A, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Alzheimers Res Ther. 2019 Jan 24;11(1):12. doi: 10.1186/s13195-018-0460-1.

16.

Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.

Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F; Euro-SCD working group.

Alzheimers Res Ther. 2019 Jan 17;11(1):8. doi: 10.1186/s13195-018-0463-y.

17.

"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".

Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R.

Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. No abstract available.

PMID:
30642435
18.

Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease.

Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Geist MA, Raket LL, Cummings JL.

J Alzheimers Dis. 2019;67(1):303-313. doi: 10.3233/JAD-180595.

PMID:
30636738
19.

Computer-assisted prediction of clinical progression in the earliest stages of AD.

Rhodius-Meester HFM, Liedes H, Koikkalainen J, Wolfsgruber S, Coll-Padros N, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, Slot RER, Verfaillie SCJ, Scheltens P, Tijms BM, Lötjönen J, van der Flier WM.

Alzheimers Dement (Amst). 2018 Oct 8;10:726-736. doi: 10.1016/j.dadm.2018.09.001. eCollection 2018.

20.

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, Rami L, Lladó A, Molinuevo JL, Tainta M, Clarimón J, Spires-Jones T, Blesa R, Fortea J, Martínez-Lage P, Sánchez-Valle R, Sabidó E, Bayés À, Belbin O.

Mol Cell Proteomics. 2019 Mar;18(3):546-560. doi: 10.1074/mcp.RA118.001290. Epub 2019 Jan 3.

PMID:
30606734
21.

The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD).

Marchant NL, Barnhofer T, Klimecki OM, Poisnel G, Lutz A, Arenaza-Urquijo E, Collette F, Wirth M, Schild AK, Coll-Padrós N, Reyrolle L, Horney D, Krolak-Salmon P, Molinuevo JL, Walker Z, Maillard A, Frison E, Jessen F, Chételat G; SCD-WELL Medit-Ageing Research Group.

Alzheimers Dement (N Y). 2018 Dec 14;4:737-745. doi: 10.1016/j.trci.2018.10.010. eCollection 2018.

22.

Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort.

Sánchez-Benavides G, Grau-Rivera O, Suárez-Calvet M, Minguillon C, Cacciaglia R, Gramunt N, Falcon C; ALFA Study, Gispert JD, Molinuevo JL.

Alzheimers Res Ther. 2018 Dec 20;10(1):123. doi: 10.1186/s13195-018-0449-9.

23.

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia.

Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer's Disease Neuroimaging Initiative; DESCRIPA working group; INSIGHT-preAD study group; SCD-I working group, van der Flier WM.

Alzheimers Dement. 2019 Mar;15(3):465-476. doi: 10.1016/j.jalz.2018.10.003. Epub 2018 Dec 13.

24.

CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease.

Lopez-Font I, Iborra-Lazaro G, Sánchez-Valle R, Molinuevo JL, Cuchillo-Ibañez I, Sáez-Valero J.

Clin Chim Acta. 2019 Mar;490:6-11. doi: 10.1016/j.cca.2018.12.012. Epub 2018 Dec 12.

PMID:
30552869
25.

Current state of Alzheimer's fluid biomarkers.

Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O'Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, Tong G, Trojanowski JQ, Zetterberg H, Blennow K.

Acta Neuropathol. 2018 Dec;136(6):821-853. doi: 10.1007/s00401-018-1932-x. Epub 2018 Nov 28. Review.

26.

Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program.

Cummings JL, Atri A, Ballard C, Boneva N, Frölich L, Molinuevo JL, Raket LL, Tariot PN.

Alzheimers Res Ther. 2018 Nov 24;10(1):116. doi: 10.1186/s13195-018-0443-2.

27.

Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity.

Jovicich J, Babiloni C, Ferrari C, Marizzoni M, Moretti DV, Del Percio C, Lizio R, Lopez S, Galluzzi S, Albani D, Cavaliere L, Minati L, Didic M, Fiedler U, Forloni G, Hensch T, Molinuevo JL, Bartrés Faz D, Nobili F, Orlandi D, Parnetti L, Farotti L, Costa C, Payoux P, Rossini PM, Marra C, Schönknecht P, Soricelli A, Noce G, Salvatore M, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Frisoniand GB; and the PharmaCog Consortium.

J Alzheimers Dis. 2019;69(1):15-35. doi: 10.3233/JAD-180158.

PMID:
30400088
28.

Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, Schmidt ME, Visser PJ, Waldman A, Wardlaw J, Haller S, Barkhof F.

Alzheimers Res Ther. 2018 Oct 30;10(1):112. doi: 10.1186/s13195-018-0438-z.

29.

AMYPAD Diagnostic and Patient Management Study: Rationale and design.

Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N.

Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16.

30.

Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies.

Hu X, Teunissen CE, Spottke A, Heneka MT, Düzel E, Peters O, Li S, Priller J, Buerger K, Teipel S, Laske C, Verfaillie SCJ, Barkhof F, Coll-Padrós N, Rami L, Molinuevo JL, van der Flier WM, Jessen F.

Alzheimers Dement. 2019 Feb;15(2):185-193. doi: 10.1016/j.jalz.2018.09.002. Epub 2018 Oct 12.

PMID:
30321506
31.

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease.

Shaw LM, Arias J, Blennow K, Galasko D, Molinuevo JL, Salloway S, Schindler S, Carrillo MC, Hendrix JA, Ross A, Illes J, Ramus C, Fifer S.

Alzheimers Dement. 2018 Nov;14(11):1505-1521. doi: 10.1016/j.jalz.2018.07.220. Epub 2018 Oct 10. Review.

32.

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K.

Nat Rev Neurol. 2018 Nov;14(11):639-652. doi: 10.1038/s41582-018-0079-7. Review.

33.

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.

Ten Kate M, Redolfi A, Peira E, Bos I, Vos SJ, Vandenberghe R, Gabel S, Schaeverbeke J, Scheltens P, Blin O, Richardson JC, Bordet R, Wallin A, Eckerstrom C, Molinuevo JL, Engelborghs S, Van Broeckhoven C, Martinez-Lage P, Popp J, Tsolaki M, Verhey FRJ, Baird AL, Legido-Quigley C, Bertram L, Dobricic V, Zetterberg H, Lovestone S, Streffer J, Bianchetti S, Novak GP, Revillard J, Gordon MF, Xie Z, Wottschel V, Frisoni G, Visser PJ, Barkhof F.

Alzheimers Res Ther. 2018 Sep 27;10(1):100. doi: 10.1186/s13195-018-0428-1.

34.

Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.

Albani D, Marizzoni M, Ferrari C, Fusco F, Boeri L, Raimondi I, Jovicich J, Babiloni C, Soricelli A, Lizio R, Galluzzi S, Cavaliere L, Didic M, Schönknecht P, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Bocchio L, Salvatore M, Rossini PM, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Forloni G, Frisoni GB; PharmaCog Consortium.

J Alzheimers Dis. 2019;69(1):37-48. doi: 10.3233/JAD-180321.

PMID:
30149449
35.

Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.

Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, Gispert JD, Molinuevo JL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.

36.

Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline.

Sánchez-Benavides G, Grau-Rivera O, Cacciaglia R, Suárez-Calvet M, Falcon C, Minguillon C, Gramunt N, Sala-Vila A, Gispert JD, Molinuevo JL.

J Alzheimers Dis. 2018;65(1):181-191. doi: 10.3233/JAD-180378.

37.

MRI-Based Screening of Preclinical Alzheimer's Disease for Prevention Clinical Trials.

Casamitjana A, Petrone P, Tucholka A, Falcon C, Skouras S, Molinuevo JL, Vilaplana V, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;64(4):1099-1112. doi: 10.3233/JAD-180299.

PMID:
30010132
38.

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data.

Bos I, Vos SJB, Jansen WJ, Vandenberghe R, Gabel S, Estanga A, Ecay-Torres M, Tomassen J, den Braber A, Lleó A, Sala I, Wallin A, Kettunen P, Molinuevo JL, Rami L, Chetelat G, de la Sayette V, Tsolaki M, Freund-Levi Y, Johannsen P; Alzheimer's Disease Neuroimaging Initiative, Novak GP, Ramakers I, Verhey FR, Visser PJ.

Front Aging Neurosci. 2018 Jun 25;10:193. doi: 10.3389/fnagi.2018.00193. eCollection 2018.

39.

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.

Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, Molinuevo JL, Wallin A, Lleó A, Popp J, Martinez-Lage P, Baird A, Dobson R, Legido-Quigley C, Sleegers K, Van Broeckhoven C, Bertram L, Ten Kate M, Barkhof F, Zetterberg H, Lovestone S, Streffer J, Visser PJ.

Alzheimers Res Ther. 2018 Jul 6;10(1):64. doi: 10.1186/s13195-018-0396-5.

40.

Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging.

Cacciaglia R, Molinuevo JL, Sánchez-Benavides G, Falcón C, Gramunt N, Brugulat-Serrat A, Grau O, Gispert JD; ALFA Study.

Hum Brain Mapp. 2018 Nov;39(11):4565-4579. doi: 10.1002/hbm.24306. Epub 2018 Jul 4.

41.

Wishes and preferences for an online lifestyle program for brain health-A mixed methods study.

Wesselman LMP, Schild AK, Coll-Padros N, van der Borg WE, Meurs JHP, Hooghiemstra AM, Slot RER, Sannemann L, Rami L, Molinuevo JL, Bouwman FH, Jessen F, van der Flier WM, Sikkes SAM; Euro-SCD working group.

Alzheimers Dement (N Y). 2018 Apr 9;4:141-149. doi: 10.1016/j.trci.2018.03.003. eCollection 2018.

42.

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.

Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K.

Alzheimers Dement. 2018 Oct;14(10):1313-1333. doi: 10.1016/j.jalz.2018.05.008. Epub 2018 Jun 23. Review.

PMID:
29940161
43.

Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers.

Marizzoni M, Ferrari C, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ribaldi F, Rossini PM, Schönknecht P, Salvatore M, Soricelli A, Hensch T, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium.

J Alzheimers Dis. 2019;69(1):3-14. doi: 10.3233/JAD-180152.

PMID:
29914031
44.

New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia.

Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gold M, Kukull WA, Mohs R, Gauthier S, Molinuevo JL, Zetterberg H, Khachaturian ZS.

Alzheimers Dement. 2018 Jun;14(6):703-706. doi: 10.1016/j.jalz.2018.05.002. Epub 2018 May 26. No abstract available.

PMID:
29842864
45.

White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes.

Operto G, Cacciaglia R, Grau-Rivera O, Falcon C, Brugulat-Serrat A, Ródenas P, Ramos R, Morán S, Esteller M, Bargalló N, Molinuevo JL, Gispert JD; ALFA Study.

Alzheimers Res Ther. 2018 May 24;10(1):48. doi: 10.1186/s13195-018-0375-x.

46.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

47.

Effects of APOE-ε4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease.

Cacciaglia R, Molinuevo JL, Falcón C, Brugulat-Serrat A, Sánchez-Benavides G, Gramunt N, Esteller M, Morán S, Minguillón C, Fauria K, Gispert JD; ALFA study.

Alzheimers Dement. 2018 Jul;14(7):902-912. doi: 10.1016/j.jalz.2018.01.016. Epub 2018 Mar 28.

48.

European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials.

Vermunt L, Veal CD, Ter Meulen L, Chrysostomou C, van der Flier W, Frisoni GB, Guessous I, Kivipelto M, Marizzoni M, Martinez-Lage P, Molinuevo JL, Porteous D, Ritchie K, Scheltens P, Ousset PJ, Ritchie CW, Luscan G, Brookes AJ, Visser PJ.

Alzheimers Dement. 2018 Jun;14(6):837-842. doi: 10.1016/j.jalz.2018.02.010. Epub 2018 Mar 28.

PMID:
29604264
49.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
50.

The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades.

Molinuevo JL, Minguillon C, Rami L, Gispert JD.

J Alzheimers Dis. 2018;62(3):1067-1077. doi: 10.3233/JAD-170698. Review.

Supplemental Content

Loading ...
Support Center